FDA panel debates label change on SSRI use during pregnancy
Regulatory NewsJeff Craven
Advisory committeesPharmaceuticalsPharmacovigilance/postmarket surveillanceProduct LifecycleUnited StatesRegulatory NewsJeff CravenAdvisory committeesPharmaceuticalsPharmacovigilance/postmarket surveillanceProduct LifecycleUnited States